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sia (r=0.57, p<0.001) as well as percent area stenosis (r=0.56, p<0.001). The mean inti-
mal cross sectional area was 2.47±1.67 in the control arteries compared to 0.52±0.52
(p<0.003) in the SU11218 treated arteries. The mean number of adventitial microvessels
in the stented segment was significantly decreased in SU11218 group (16.71±3.82 ver-
sus 24.86±9.76 in the control group, p< 0.001).
Conclusions: Coronary stenting results in a prominent angiogenic response in the arterial
adventitia that strongly correlates with the intimal hyperplasia and percent area stenosis.
The tyrosine kinase receptor inhibitor, SU11218, markedly inhibited both the adventitial
angiogenic response and in-stent hyperplastic response after stentingAngiogenic inhibi-
tors such as SU11218 may have important therapeutic implications for preventing in-
stent restenosis.
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Background: In-stent restenosis is a complex process mediated by inflammatory cytok-
ines and growth factors, which regulate inflammatory cells recruitment to the vessel wall
as well as vascular smooth muscle cell migration and proliferation. Since intracellular
copper metabolism plays a crucial role in the stress-induced release of FGF-1 and IL1α,
both of which are important for neointima development after vessel injury, we examined
the effect of tetrathiomolybdate (TTM), a clinically proven copper chelator, on in-stent
restenosis in a porcine stent model.
Methods: Seventeen stents were implanted in the left anterior descending coronary
artery of 17 male pigs using a stent to artery overstretch ratio of 1.2:1. Nine pigs (Gr.1)
were treated daily with 10 mg/kg TTM p.o. starting 14 days prior to stent implantation and
continuing until sacrifice at 28 days follow-up, whereas 8 pigs (Gr.2) served as controls.
The effect of TTM on in-stent restenosis was assessed by biplane quantitative coronary
angiography before and immediately after stenting as well as at 28 days follow-up. Serum
ceruloplasmin activity, an indirect indicator of total copper level, was measured weekly.
Results: The two groups were comparable regarding baseline data including animal age
and body weight, stent size, vessel reference diameter, and ceruloplasmin activity. Post-
interventional minimal lumen diameter and overstretch ratio were similar for both groups.
However, at 28 days follow-up, there was a marked difference of all parameters relevant
to the in-stent restenosis in favor of the TTM-treated group: minimal lumen diameter was
2.2±0.6 mm in Gr.1 vs. 1.5±0.4 mm in Gr.2, p<0.05 and diameter stenosis was 22±18%
in Gr.1 vs. 42±17% in Gr.2, p<0.05. During the entire follow-up period, ceruloplasmin
activity in the TTM group was significantly decreased from 50% to 80% (p<0.0001) of its
baseline level.
Conclusions: This study is the first to provide evidence that copper chelation by tetrathi-
omolybdate can markedly prevent in-stent restenosis. Our data also suggest that this
simple and inexpensive approach is a potential tool in the management of vascular rest-
enosis after percutaneous interventions in clinical settings.
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Background: Although diffuse in-stent restenosis (ISR) has been known to be refractory
to repeated percutaneous coronary intervention (PCI), long-term outcome of those
patients has not yet been established. Methods: To evaluate long-term (7-11yrs) clinical
outcome after ISR, follow-up (FU) information was analyzed in 78 patients (pts) or 78
lesions with Palmaz-Schatz stent ISR at 6-month FU quantitative angiography. According
to the angiographic appearance, ISR occurred diffusely (lesion length>10mm) in 34
pts(44%), focally inside the stent in 26 pts(33%) and focally at the stent border in 18
pts(23%). Repeat PCI was performed in 58 pts(74%). Recurrent restenosis in the diffuse
type (85%) were significantly higher than those in the focally intra-stent type (12%) and in
the border type (19%)(P=0.0001). Mean FU interval was 8.1+1.0 yrs among 57 surviving
pts. FU rate was 98% at 8 yrs. Results: Event-free survival (EFS) rates at 8 yrs were as
follows: cardiac death 92%, death 80%, death/myocardial infarction (MI)/coronary artery
bypass surgery (CABG) 67%, death/MI/CABG/target lesion PCI 14%, death/MI/CABG/
any PCI 6%. EFS rates (Death/MI/CABG) at 8 yrs in the diffuse type (68%) were similar
with in the focally intra-stent type (51%) and focally at the stent border type
(88%)(P=0.17). Conclusion: Although PCI for diffuse ISR was associated with very high
recurrent restenosis rates rather than the other types of ISR, long-term clinical outcome
at 7-11 yrs of FU were similar among the three groups. 
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Background: The occurrence of balloon slippage (“watermelon seeding”) (WMS) during
treatment of patients with in-stent restenosis (ISR) has been described, but predisposing
factors and the potential implications of this phenomenon remain unknown. Methods: In
the Restenosis Intra-stent: Balloon angioplasty vs elective Stenting (RIBS) randomized
study, 450 patients with ISR were included. Of these, 42 patients (9%) presented WMS
during the procedure. Results: WMS was detected in 26 patients (12%) in the balloon
arm and 16 (7%) in the stent arm (p= 0.11). In the stent arm, WMS was only noticed dur-
ing balloon predilation, never during stent implantation. As compared with 408 patients
without WMS, patients with WMS tended to have more severe [% diameter stenosis
(79+13% vs 76+12%, p=0.08), TIMI flow 0-1 (21% vs 8%, p=0.01)] and diffuse (length
>15 mm: 48% vs 34%, p=0.08) ISR lesions. Patients with WMS required more balloon
inflations (5.7+2.2 vs 3.5+1.9, p<0.001), longer total inflation time (184+116 vs 150+106
seconds, p=0.04), and had more frequently cross-over to stenting or ended the proce-
dure with residual dissections (26% vs 14.5%, p=0.04) and eventually obtained poorer
acute results (minimal lumen diameter 2.35+0.5 vs 2.53+0.5 mm, p=0.03). In addition, at
6-month follow-up patients with WMS had a smaller minimal lumen diameter (1.26+0.7
vs 1.61+0.7mm, p= 0.007) and a higher restenosis rate (56% vs 37%, p=0.017). On
logistic regression analysis the WMS phenomenon emerged as an independent predictor
of recurrent restenosis (Adjusted RR 2.1, 95%CI 1.1-4.1, p=0.04). Conclusions: The
WMS phenomenon is frequently seen during treatment of patients with ISR. Long and
severe lesions appear to predispose to this technical problem that never occurs during
stent deployment. In patients with ISR, WMS is associated with poorer acute and long-
term angiographic results. 
1121-55 The Presence of Side Branches Impacts Periprocedural 
Enzyme Elevation and Clinical Outcome in Patients 
Undergoing Brachytherapy for In-Stent Restenosis
Pramod K. Kuchulakanti, Seung-Woon Rha, Andrew E. Ajani, Natalie Gevorkian, Ellen 
Pinnow, Rebecca Torguson, Augusto Pichard, Lowell F. Satler, Kenneth Kent, Joseph 
Lindsay, Ron Waksman, Washington Hospital Center, Washington, DC
Background: Major side branch (diameter >1.5mm, SB) involvement within the lesion
subjected for Percutaneous Coronary Intervention (PCI) is known to be a contributing
factor for periprocedural cardiac enzyme elevation (CE). We aimed to assess the impact
of SB on CE and 6 month outcome in-patients undergoing brachytherapy for in-stent res-
tenosis. (ISR).
Methods: Retrospective analysis of the data of 248 consecutive patients with a single
vessel ISR with SB (Gp1, n=146) and without SB (Gp2, n=102) who underwent brachy-
therapy using both beta and gamma emitters was conducted. The procedural complica-
tions, CE, in-hospital course and 6 month clinical outcome were compared.
Results: The baseline patient and lesion characteristics were similar among the groups.
Procedural variables were similar except that stent usage was more in Gp1. Baseline
Creatine Phosphokinase (CPK)-MB levels were similar, but post procedure CPK-MB lev-
els were higher in Gp1. In hospital complications were similar between the two groups.
Six months follow up revealed higher restenosis and Major Adverse Cardiac Events
(MACE) in Gp1.
Conclusions: Presence of SB within the restenotic segment when treated with PCI and
brachytherapy is associated with higher preocedural CE and MACE at six months. Spe-
cial care should taken when treating ISR lesions with SB.
